Illumina investment push


Gene sequencing company Illumina has struck a $450 million (£280 million) deal to buy privately owned US firm Verinata Health, which specialises in non-invasive tests for early identification of foetal chromosomal abnormalities.

The deal follows the collapse of Roche’s $5.7 billion hostile bid for Illumina in early 2012 – which the company rejected. It also follows Illumina’s acquisition of BlueGnome, a University of Cambridge spinout that has developed a test for counting chromosomes in a cell.

Illumina will pay $350 million up front, plus up to $100 million in milestone payments.

 


Related Content

Rapid DNA sequencing cleared for the clinic

21 November 2013 Business

news image

Illumina’s ‘next-generation’ MiSeqDx platform gets US approval

Sequencing in the fast lane

25 July 2012 Premium contentFeature

news image

Phillip Broadwith gets up to speed with the latest developments in DNA sequencing technology

Most Read

Enthralled by evaporation

20 February 2015 Organic Matter

news image

A giant rotary evaporator is a mesmerising thing, says Chemjobber, but the plant requires a different approach

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Caramel colour in soft drinks linked to cancer

26 February 2015 News and Analysis

news image

Regulatory bodies and researchers sceptical of study on 4-MEI found in food colour

Nanoporous methane storage – an impossible target?

18 February 2015 Research

news image

Identifying performance limits for nanoporous materials highlights that current methane storage goals might be unrealistic